Manila Times Business
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent in vivo CAR-Texpansion without lymphodepletionNo dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1-2, and none required glucocorticoids for CRS managementAdditional translational data showed rapid vector clearance, poly
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Gatchalian on continuing education in emergencies: Strengthen LGU involvement
Just now
DepEd, Bayugan City ink landmark agreement to boost School-Based Feeding Program
Just now
Ddrops® Championed Active Childhoods and Healthy Growth at Aqua Champs League Fest 2026 Malaysia
Just now
Ruvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02
Just now